These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 11535505)

  • 1. Deletions of the derivative chromosome 9 occur at the time of the Philadelphia translocation and provide a powerful and independent prognostic indicator in chronic myeloid leukemia.
    Huntly BJ; Reid AG; Bench AJ; Campbell LJ; Telford N; Shepherd P; Szer J; Prince HM; Turner P; Grace C; Nacheva EP; Green AR
    Blood; 2001 Sep; 98(6):1732-8. PubMed ID: 11535505
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Double jeopardy from a single translocation: deletions of the derivative chromosome 9 in chronic myeloid leukemia.
    Huntly BJ; Bench A; Green AR
    Blood; 2003 Aug; 102(4):1160-8. PubMed ID: 12730117
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Derivative chromosome 9 deletions in chronic myeloid leukemia: poor prognosis is not associated with loss of ABL-BCR expression, elevated BCR-ABL levels, or karyotypic instability.
    Huntly BJ; Bench AJ; Delabesse E; Reid AG; Li J; Scott MA; Campbell L; Byrne J; Pinto E; Brizard A; Niedermeiser D; Nacheva EP; Guilhot F; Deininger M; Green AR
    Blood; 2002 Jun; 99(12):4547-53. PubMed ID: 12036887
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Study of deletion of derivative chromosome 9 in patients with Ph+ chronic myeloid leukemia].
    Wu W; Xue YQ; Wu YF; Pan JL; Shen J
    Zhonghua Xue Ye Xue Za Zhi; 2006 Mar; 27(3):183-6. PubMed ID: 16792921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Large deletions at the t(9;22) breakpoint are common and may identify a poor-prognosis subgroup of patients with chronic myeloid leukemia.
    Sinclair PB; Nacheva EP; Leversha M; Telford N; Chang J; Reid A; Bench A; Champion K; Huntly B; Green AR
    Blood; 2000 Feb; 95(3):738-43. PubMed ID: 10648381
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A study on the incidence of ABL gene deletion on derivative chromosome 9 in chronic myelogenous leukemia by interphase fluorescence in situ hybridization and its association with disease progression.
    Lee DS; Lee YS; Yun YS; Kim YR; Jeong SS; Lee YK; She CJ; Yoon SS; Shin HR; Kim Y; Cho HI
    Genes Chromosomes Cancer; 2003 Jul; 37(3):291-9. PubMed ID: 12759927
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular cytogenetic characterization of variant Philadelphia translocations in chronic myeloid leukemia: genesis and deletion of derivative chromosome 9.
    Bennour A; Sennana H; Laatiri MA; Elloumi M; Khelif A; Saad A
    Cancer Genet Cytogenet; 2009 Oct; 194(1):30-7. PubMed ID: 19737651
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The prognostic significance of derivative chromosome 9 deletions in chronic myeloid leukemia].
    Wu W; Li JY; Shen YF; Cao XS; Qiu HR; Xu W
    Zhonghua Nei Ke Za Zhi; 2007 May; 46(5):386-8. PubMed ID: 17637307
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genomic deletions on other chromosomes involved in variant t(9;22) chronic myeloid leukemia cases.
    Albano F; Specchia G; Anelli L; Zagaria A; Storlazzi CT; Buquicchio C; Roberti MG; Liso V; Rocchi M
    Genes Chromosomes Cancer; 2003 Apr; 36(4):353-60. PubMed ID: 12619159
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical implications of fluorescence in situ hybridization analysis in 13 chronic myeloid leukemia cases: Ph-negative and variant Ph-positive.
    Yehuda O; Abeliovich D; Ben-Neriah S; Sverdlin I; Cohen R; Varadi G; Orr R; Ashkenazi YJ; Heyd J; Lugassy G; Ben Yehuda D
    Cancer Genet Cytogenet; 1999 Oct; 114(2):100-7. PubMed ID: 10549264
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interphase fluorescence in situ hybridization studies for the detection of 9q34 deletions in chronic myelogenous leukemia: a practical approach to clinical diagnosis.
    Aoun P; Wiggins M; Pickering D; Foran J; Rasheed H; Pavletic SZ; Sanger W
    Cancer Genet Cytogenet; 2004 Oct; 154(2):138-43. PubMed ID: 15474149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deletion of the 5'ABL region in Philadelphia chromosome positive chronic myeloid leukemia: frequency, origin and prognosis.
    Morel F; Ka C; Le Bris MJ; Herry A; Morice P; Bourquard P; Abgrall JF; Berthou C; De Braekeleer M
    Leuk Lymphoma; 2003 Aug; 44(8):1333-8. PubMed ID: 12952226
    [TBL] [Abstract][Full Text] [Related]  

  • 13. On the genesis and prognosis of variant translocations in chronic myeloid leukemia.
    Gorusu M; Benn P; Li Z; Fang M
    Cancer Genet Cytogenet; 2007 Mar; 173(2):97-106. PubMed ID: 17321324
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The negative prognostic impact of derivative 9 deletions in patients who received hydroxyurea treatment for chronic myelogenous leukemia in the chronic phase.
    Li JY; Xu W; Wu W; Zhu Y; Qiu HR; Zhang R; Zhang SJ; Qian SX
    Onkologie; 2008 Nov; 31(11):585-9. PubMed ID: 19145090
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Deletions of derivative chromosome 9 in 138 patients with chronic myeloid leukemia].
    Wang L; Qian SX; Qiu HR; Wang R; Zhang SJ; Miao KR; Fan L; Xu W; Li JY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Apr; 17(2):281-4. PubMed ID: 19379551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Survival implications of molecular heterogeneity in variant Philadelphia-positive chronic myeloid leukaemia.
    Reid AG; Huntly BJ; Grace C; Green AR; Nacheva EP
    Br J Haematol; 2003 May; 121(3):419-27. PubMed ID: 12716364
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of Philadelphia chromosome-negative BCR-ABL-positive chronic myelogenous leukemia by hypermetaphase fluorescence in situ hybridization.
    Seong D; Kantarjian HM; Albitar M; Arlinghaus R; Xu J; Talpaz M; Rios MB; Guo JQ; O'Brien S; Siciliano M
    Ann Oncol; 1999 Aug; 10(8):955-9. PubMed ID: 10509158
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deletion of any part of the BCR or ABL gene on the derivative chromosome 9 is a poor prognostic marker in chronic myelogenous leukemia.
    Lee YK; Kim YR; Min HC; Oh BR; Kim TY; Kim YS; Cho HI; Kim HC; Lee YS; Lee DS
    Cancer Genet Cytogenet; 2006 Apr; 166(1):65-73. PubMed ID: 16616113
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of the breakpoint cluster region-ABL fusion in chronic myeloid leukemia with variant Philadelphia chromosome translocations by in situ hybridization.
    Tosi S; Cabot G; Giudici G; Attuati V; Morandi P; Rambaldi A; Döhner H; Biondi A
    Cancer Genet Cytogenet; 1996 Jul; 89(2):153-6. PubMed ID: 8697423
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Coexistence of Philadelphia chromosome positive cells with and without der(9) deletion in a patient with chronic myelogenous leukemia.
    Xinh PT; Vu HA; Nghia H; Binh NT; Van Be T; Van Binh T; Tokunaga K; Sato Y
    Cancer Genet Cytogenet; 2006 Jan; 164(2):122-7. PubMed ID: 16434314
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.